← Back to Home

Hansa Partners with Cradle to Let Experimental Data Guide Protein Design for Autoimmune Therapies

The partnership will bring AI protein engineering into Hansa’s drug discovery workflow to adjust multiple molecular properties simultaneously. Whether it can save development time remains to be demonstrated by experimental results from the partnership itself.

By SURL BioNews

Designing proteins as drugs begins with identifying promising molecules; each subsequent round of modifications requires experiments to determine whether they are actually better. Swedish biotech company Hansa Biopharma announced a partnership with Cradle on October 1, 2026, with plans to have AI continuously learn from its own experimental data to help develop novel immunomodulatory therapies for severe autoimmune diseases.

According to announcements from both companies, Hansa will use Cradle’s protein design and engineering platform across its drug discovery pipeline, covering the design, optimization, and further advancement of candidate molecules. A same-day report by Nordic Life Science also confirmed that the partnership will bring the platform into Hansa’s research and development work. What has been announced so far is the introduction of a research and development tool; no new drug outcomes resulting from the partnership have yet been presented.

Hansa said that, after evaluating multiple AI models and vendors, the team chose Cradle for reasons including support starting from initial hit identification, simultaneous optimization of multiple parameters, and active learning using Hansa’s own experimental data. The idea is to repeatedly connect computational design with laboratory testing, then use the test results to guide the next round of molecular adjustments. However, the announcement did not specify which properties would be optimized or disclose the size of the dataset or the accuracy of the model’s predictions.

The arrangement aligns with Hansa’s existing direction in protein drug development. The company has enzyme technology that cleaves immunoglobulin G (IgG) antibodies, and its imlifidase is already marketed in Europe under the brand name Idefirix for kidney transplantation in highly sensitized patients. However, clinical experience with an existing product cannot directly be regarded as validation of the new AI platform. The companies also did not explain whether this partnership covers specific existing molecules or which autoimmune disease programs it targets.

On speed, Cradle claims that its customers have reported reductions in development timelines of up to 18 months. This is the vendor’s general account of other customers’ experiences, rather than a result already achieved by the Hansa partnership. The announcement provided no comparison baseline, project conditions, or data sufficient to assess whether the results could be reproduced, so it cannot yet be used to estimate how much time and cost Hansa might save.

The companies also did not disclose the financial value of the partnership, a timeline for advancing drug candidates, or animal and human trial data generated by the partnership. Based on the information currently available, the most concrete development is Hansa’s integration of experimental data and AI design into a single research and development workflow. Whether this workflow can produce molecules better suited for development will depend on comparative experiments disclosed in the future. For patients, evidence of each candidate drug’s safety and efficacy will still be needed.

References

  1. TradingView
  2. Cradle
  3. PR Newswire — Cradle and Hansa Biopharma AB
  4. Nordic Life Science